1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,646 | 1,730 | 13:05 | |
| 1,662 | 1,710 | 11.09. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | SynAct Pharma: Further Analysis of the Phase 2b ADVANCE Study Reinforces Phase 2b EXPAND Results and Supports Phase 3 Development - FDA Discussions on Trial Design Planned for Q4 2026 | 370 | ACCESS Newswire | LUND, SE / ACCESS Newswire / September 7, 2026 / SynAct Pharma AB (publ) ("SynAct")(STO:SYNACT), a clinical-stage biotechnology company focused on treating inflammation through a novel therapeutic approach... ► Artikel lesen | |
| 03.09. | SynAct Pharma's CEO and CSO Sell Shares | 218 | ACCESS Newswire | LUND, SE / ACCESS Newswire / September 3, 2026 / SynAct Pharma AB (STO:SYNACT) ("SynAct Pharma" or the "Company") today announces that the Company's Chief Executive Officer, Jeppe Øvlesen, and the Company's... ► Artikel lesen | |
| SYNACT PHARMA Aktie jetzt für 0€ handeln | |||||
| 20.08. | SynAct Pharma AB: SynAct Pharma publishes Q2 2026 interim results | 194 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") today publishes the interim report for the second quarter 2026.
"With new capital secured and active partnering discussions underway, we are positionedto pursue the... ► Artikel lesen | |
| 19.08. | SynAct Pharma AB: SynAct Pharma progresses first commercial agreement on resomelagon for treatment of dengue in Brazil - term sheet signed | 215 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, today announces that the company has signed... ► Artikel lesen | |
| 05.08. | SynAct Pharma AB: SynAct Pharma receives favorable US patent decision for immediate-release resomelagon tablet formulation | 567 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") today announced that the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) has issued a favorable Decision on Appeal in... ► Artikel lesen | |
| 20.07. | SynAct Pharma AB: SynAct Pharma strengthens financial position and strategic flexibility to advance partnering discussions and Phase III readiness | 788 | GlobeNewswire (Europe) | SynAct Pharma AB ("SynAct" or the "Company") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnology company developing resolution therapies for inflammatory diseases, today announced that it has... ► Artikel lesen | |
| 29.06. | SynAct Pharma AB: BIO International USA confirms growing interest in resomelagon and SynAct Pharma following the positive effects of the ADVANCE study | 802 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnology company focused on treating inflammation through resolution therapy, today provides an update following... ► Artikel lesen | |
| 15.06. | SynAct Pharma AB: Phase 2b ADVANCE study demonstrates positive effects of resomelagon in Rheumatoid Arthritis - supports phase 3 design, regulatory interactions, and partnering | 498 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, reported today that resomelagon in combination... ► Artikel lesen | |
| 12.06. | SynAct Pharma AB: SynAct obtains key US patent for resomelagon securing exclusivity until 2044 | 623 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") announced today that the United States Patent and Trademark Office (USPTO) have provided the issue notification of US patent 12,661,336 with issue date 23 June 2026... ► Artikel lesen | |
| 11.06. | SynAct Pharma AB: Report from the 2026 Annual General Meeting of SynAct Pharma AB (publ) | 453 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) held its Annual General Meeting today, Thursday 11 June 2026, at the offices of MAQS Advokatbyrå in Stockholm. Attorney Eric Ehrencrona from MAQS Advokatbyrå was elected as chairman... ► Artikel lesen | |
| 27.05. | SynAct Pharma AB: SynAct Pharma publishes Q1 2026 interim results | 376 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") today publishes the interim report for the first quarter 2026.
"As we close the first quarter of 2026, SynAct Pharma is in a stronger position than at any previous... ► Artikel lesen | |
| 06.05. | SynAct Pharma AB: SynAct Pharma completes dosing for last patient in Phase 2b ADVANCE study | 632 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, has successfully completed dosing... ► Artikel lesen | |
| 26.03. | SynAct Pharma AB: SynAct Pharma doses first patients in the Phase 2 RESOVIR-2 study with resomelagon | 289 | GlobeNewswire (Europe) | SynAct Pharma AB ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, today announces that the first patients were dosed... ► Artikel lesen | |
| 03.03. | SynAct Pharma - Multiple shots on goal in 2026 for resomelagon | 590 | Edison Investment Research | SynAct Pharma's FY25 results reflect a year of solid execution, highlighted by the continued advancement of lead asset resomelagon in the Phase IIb ADVANCE trial in rheumatoid arthritis (RA). With enrolment... ► Artikel lesen | |
| 24.02. | SynAct Pharma AB: SynAct Pharma appoints Ann Kristin Led as Chief Financial Officer | 268 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, today announced the appointment of Ann Kristin... ► Artikel lesen | |
| 18.02. | SynAct Pharma AB: SynAct Pharma Year-end Report 2025 | 321 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") today announced its Year-end Report 2025
"As we close the fourth quarter and conclude 2025, I am pleased with the steady progress SynAct Pharma has made across clinical... ► Artikel lesen | |
| 10.02. | SynAct Pharma - Resomelagon progresses in RA, viral infections | 601 | Edison Investment Research | SynAct Pharma has completed patient recruitment for its Phase IIb ADVANCE trial (n=240) in rheumatoid arthritis (RA), while initiating the Phase II RESPIRE study in hospitalised with respiratory insufficiency... ► Artikel lesen | |
| 06.02. | SynAct Pharma AB: SynAct Pharma successfully reached recruitment goal in Ph2b ADVANCE study | 529 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, has successfully reached the recruitment... ► Artikel lesen | |
| 30.01. | SynAct Pharma AB: SynAct Pharma initiates Phase 2 study in respiratory insufficiency | 465 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, today announced that it has initiated... ► Artikel lesen | |
| 19.01. | SynAct Pharma AB: SynAct Pharma appoints Malin Wikstrand as interim CFO | 264 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, today announces that Malin Wikstrand... ► Artikel lesen |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 48,170 | -1,09 % | Nicht nur Bayer verdient am Weltmarkt mit, ohne überall selbst präsent zu sein: Ein australischer Psychedelika-Anbieter setzt auf dasselbe Grundprinzip | ||
| ABBVIE | 221,30 | -0,23 % | Eli Lilly, AbbVie und Johnson & Johnson: Wie der Fünf-Milliarden-Dollar-Pharma-Run auf Psychedelika Emyria in den Fokus rückt | ||
| ELI LILLY | 962,10 | +0,06 % | Milliardenwette geplatzt: Pharma-Aktie kassiert schweren Rückschlag | © Foto: Sebastian Gollnow/dpaNovartis enttäuscht mit Pelacarsen und verliert an der Börse deutlich. Jetzt wächst der Druck auf die Pipeline Enthaltene Werte: US0311621009,US5324571083,CH0012005267Den... ► Artikel lesen | |
| MERCK & CO | 124,34 | +0,16 % | Mercks 30-Milliarden-Dollar-Blockbuster bekommt neue Konkurrenz - warum Big Pharma schon die nächste Plattform sucht | ||
| BRISTOL-MYERS SQUIBB | 54,76 | -0,22 % | Bristol-Myers Squibb Company: National Coalition of Pharmaceutical Industry, Academic, and Nonprofit Partners Launches Fifth Winn CIPP Cohort | NORTHAMPTON, MA / ACCESS Newswire / September 9, 2026 / Organizations Across Sectors Unite Through the Winn Awards to Advance Better Science For All Previously published by the Robert A. Winn Excellence... ► Artikel lesen | |
| INNOCAN PHARMA | 1,240 | -0,80 % | Innocan Pharma Corporation: Innocan Pharma Announces Private Placement of Units | HERZLIYA, Israel and CALGARY, Alberta, Sept. 9, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that... ► Artikel lesen | |
| DOCMORRIS | 10,580 | +0,19 % | DocMorris tauscht Wandelanleihe 2028 gegen 2031 | DocMorris nimmt seine Kapitalstruktur unter die Lupe und legt eine neue Wandelanleihe über rund 100 Mio. CHF auf. Die Emission soll unter anderem dazu dienen, die ausstehende Wandelanleihe mit Fälligkeit... ► Artikel lesen | |
| INCYTE | 105,35 | +0,52 % | Cantor Fitzgerald reiterates Neutral on Incyte stock after conference | ||
| SINOPHARM | 1,708 | 0,00 % | Harbour BioMed and Sinopharm Enter Strategic Collaboration to Establish Innovation R&D Consortium | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 27, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed... ► Artikel lesen | |
| HAPPY BELLY FOOD GROUP | 0,930 | 0,00 % | Happy Belly Food Group Inc.: Heal Wellness Multi-Unit Franchisee in Alberta Secures Their 14th Real-Estate Location in Calgary's Seton Neighborhood | Toronto, Ontario--(Newsfile Corp. - September 10, 2026) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leading consolidator of emerging restaurant brands... ► Artikel lesen | |
| COMPASS PATHWAYS | 12,400 | 0,00 % | Compass Pathways vergibt Schulungszuschuss an Strata Mental Health für COMP360-Therapie | ||
| HIGH TIDE | 2,140 | 0,00 % | High Tide setzt seine Expansion in Kanada mit drei neuen Canna Cabana-Standorten fort | CALGARY, AB, 31. August 2026 / IRW-Press / High Tide Inc. ("High Tide" oder das "Unternehmen") (Nasdaq: HITI) (TSXV: HITI) (FWB: 2LYA) - das erfolgreiche, auf
den Einzelhandel fokussierte Unternehmen... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 254,00 | +3,25 % | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement | $15 million payment fulfills previously scheduled tranche under royalty-based financing agreement, bringing total capital received from Ligand to $40 million to date in exchange for tiered royalty... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 206,30 | -2,73 % | UBS hebt Kursziel für Jazz Pharmaceuticals nach Ziihera-Zulassung an | ||
| SELLAS LIFE SCIENCES | 10,000 | +0,60 % | DesignRush: Brooke Sellas Joins DesignRush Podcast on Social Media's Revenue Risk | Miami, Florida--(Newsfile Corp. - June 23, 2026) - The latest episode of the DesignRush Podcast features Brooke Sellas, founder and CEO of B Squared Media. The episode explores why companies risk... ► Artikel lesen |
SYNACT PHARMA AB gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von -0,036 (-2,14 %) liegt der Kurs bei 1,650 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SYNACT PHARMA AB finden Sie auf Wallstreet Online.